Cytospire names Sumeet Ambarkhane as CMO
UK biotech Cytospire Therapeutics, which is developing differentiated multispecific immune cell engager antibodies, today announces the appointment of Dr Sumeet Ambarkhane as chief medical officer (CMO).
Dr Ambarkhane is a physician-scientist and biotechnology executive with more than 20 years of experience in the US and Europe spanning clinical medicine, drug development, regulatory strategy and commercialization. He joins Cytospire as the company advances CYT X300, its lead pan-gamma delta T cell engager programme, towards clinical development as a potential treatment for EGFR-positive solid tumors, such as colorectal, head and neck and non-small cell lung cancers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze